CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General ...

An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

A groundbreaking study from Baylor College of Medicine explores how two types of CAR T cells target cancer, shedding light on ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases. An investigator-initiated trial is ongoing in ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor ...